Table 1.
Clinical characteristics of all study participants
| ALS (n=92) | MSA (n=43) | HC (n=48) | |
|---|---|---|---|
| Sex (Male/female) | 59/33 | 34/9 | 28/20 |
| Age (years) | |||
| 52.04±10.07 | 59.88±8.81 | 40.42±16.65 | |
| Relevant subgroups | 48 Upper limb-onset, 30 Lower limb-onset 14 Bulbar onset | 26 MSA-P, 17 MSA-C | NA |
| Age of onset (years) | 50.43±10.02 | 57.46±8.03 | NA |
| ALSFRS-R | 37.95±5.97 | NA | NA |
| Disease duration (months) | 19.30±15.48 | 29.08±25.39 | NA |
| FVC | 89.15±23.52 | NA | NA |
| BMI | 23.42±3.20 | 22.86±2.78 | 22.76±3.44 |
| Rate of disease progression (score/month) | 0.78±0.56 | NA | NA |
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, the ALS functioning rating scale-revised; BMI, body mass index; FVC, forced vital capacity; HC, healthy controls; MSA, multiple system atrophy; MSA-C, multiple system atrophy-the cerebellar type; MSA-P, multiple system atrophy-Parkinsonian type; NA, not applicable.